You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤雙鶴(600062.SH):部分產品獲得藥品補充申請批準通知書及化學原料藥上市申請批準通知書
格隆匯 04-16 16:52

格隆匯4月16日丨華潤雙鶴(600062.SH)公佈,公司全資子公司華潤紫竹藥業有限公司(簡稱“華潤紫竹”)收到了國家藥品監督管理局頒發的鹽酸奧洛他定滴眼液(簡稱“該藥品”)《藥品補充申請批準通知書》(編號:2025B01154和2025B01155);控股子公司浙江新賽科藥業有限公司(簡稱“浙江新賽科”)非諾貝特酸膽鹼原料藥(簡稱“該原料藥”)收到了國家藥監局頒發的《化學原料藥上市申請批準通知書》(編號:2025YS00306)。

本次鹽酸奧洛他定滴眼液取得《藥品補充申請批準通知書》,有助於豐富華潤紫竹眼科產品管線;非諾貝特酸膽鹼原料藥取得《化學原料藥上市申請批準通知書》,表明該原料藥已符合國家相關藥品審評技術標準,待通過GMP符合性檢查後可生產銷售至國內市場,並根據市場需求開闢國際市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account